Advaxis grants Aratana exclusive, worldwide rights to ADXS-cHER2 to treat osteosarcoma in dogs as well as three undisclosed immunotherapies to treat animal cancers

Advaxis Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Aratana Therapeutics Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$497.3m on 03/14/2014 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced